Clinical Trial News - BioPharma Dive
WEB3 days ago · Amgen claims success for two immune drugs, but results underwhelm Wall Street. Medicines the company is developing for eczema and myasthenia gravis met their objectives in Phase 3 trials. But analysts weren’t convinced they can compete with available alternatives. By Kristin Jensen • Sept. 25, 2024.
10 clinical trials to watch in the first half of 2024
WEBJan 2, 2024 · Moderna and Pfizer both reported promising results in early testing last fall and have moved on to late-stage studies. Moderna appears positioned to get to the finish line first. Results from its Phase 3 trial could be coming in the first half of this year, according to a federal database. — Delilah Alvarado.
Biotech and Pharma Industry News | BioPharma Dive
WEBBioPharma Dive provides news and analysis for biotech and biopharmaceutical executives. We cover topics like clinical trials, drug discovery and development, pharma marketing, FDA approvals and regulations, and more.
Novo’s latest obesity pill spurs major weight loss in small trial
WEBMar 7, 2024 · A newer drug Novo’s working on, CagriSema, helped obese people lose 17% of their body weight at 20 weeks, while an injectable from Viking Therapeutics was associated with 15% weight loss in 13 weeks. A pill Lilly has in Phase 3 testing, meanwhile, hit 13% weight loss at 26 weeks. Structure Therapeutics’ experimental pill produced 5% …
Summit lung cancer drug shows ‘striking’ benefit over Keytruda
WEBSep 8, 2024 · Study results showed Summit’s drug cut the risk of lung cancer progression or death by half compared to Keytruda, a finding doctors described as impressive. Published Sept. 8, 2024. Ben Fidler Senior Editor. Summit Therapeutics tested its drug ivonescimab against Keytruda in people with previously untreated lung cancer.
Roche reports survival data for new dual-acting lymphoma drug
WEBApr 15, 2024 · Roche’s new dual-acting blood cancer drug Columvi combined with chemotherapy helped people with a type of lymphoma live longer than people given Rituxan and chemo, the company said Monday. The data could help Roche persuade the Food and Drug Administration to convert Columvi’s conditional OK into a full approval.
Apellis plans FDA filing after drug success in kidney trial
WEBAug 8, 2024 · Treatment with an Apellis Pharmaceuticals drug appeared to benefit people with one of two uncommon kidney diseases, according to results from a late-stage clinical trial the biotechnology company disclosed Thursday. The drug, called pegcetacoplan and sold by Apellis as Empaveli for a rare blood disorder, reduced urine protein levels by 68% ...
Novo fills in positive picture for preventive hemophilia drug
WEBJun 24, 2024 · The data, which were presented at the International Society on Thrombosis and Haemostasis Annual Congress in Thailand, fill in a positive picture for Mim8’s effectiveness and safety. Novo had said in May that the Phase 3 trial, called Frontier-2, succeeded and shared topline findings. Among people …
Merck claims late-stage study success for RSV antibody
WEBJul 23, 2024 · An experimental Merck & Co. drug designed to protect infants from illness caused by respiratory syncytial virus succeeded in a late-stage trial, the company said Tuesday. In a statement, Merck said the therapy, an antibody called clesrovimab, met its main safety and efficacy objectives in a placebo-controlled trial involving more than 3,600 ...
8 key clinical trials to watch for the rest of 2021
WEBJun 21, 2021 · A closely watched antiviral drug could change how COVID-19 is treated. And a gene therapy could bring new hope to patients with a debilitating neurological disease. Here are eight important clinical trials to watch: Companies: Merck & Co., Ridgeback Biotherapeutics. Disease: COVID-19. Treatment type: Antiviral.